Inflammatory myofibroblastic tumour of the lung: a reactive lesion or a true neoplasm?

First described by Brunn in 1937, inflammatory myofibroblastic tumour (IMT) represents an extremely rare type of inflammatory pseudo-tumour that appears most commonly in children and young individuals with a prevalence ranging from 0.04% to 0.7% irrespective of the gender and race of the world population (1,2). There has been an ongoing controversy whether an IMT is a reactive lesion or a true neoplasm (3). This has been revealed in a large number of individual case reports and series with subtle differences in their clinico-pathological findings and the results of the treatment provided. Purpose of the paper is, through a literature review, to identify the clinical approach of this rare tumour highlighting key features and the available management options